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Abstract Previously, we identified valosin-containing pro-
tein (VCP) as a mediator of ER stress-induced cell death.
Mutations in the VCP gene including R93, R155, and R191
have been described that manifest clinically as hereditary
inclusion body myopathy with Paget’s disease of bone and
frontotemporal dementia. In addition, other studies have
demonstrated that as a consequence of a mutation generated
in the second ATP binding domain of VCP (K524A), cells
accumulated large cytoplasmic vacuoles and underwent
programmed cell death. In order to better understand the
biochemical and molecular consequences of the clinically
relevant VCP mutations as well as the genetically engineered
ATPase-inactive mutant K524A and any relationship these
may have to ER stress-induced cell death, we introduced
analogous mutations separately and together into the human
VCP gene and evaluated their effect on proteasome activity,
Huntingtin protein aggregation and ER stress-induced cell
death. Our results indicate that the VCP K524A mutant and
the triple mutant VCP R93C-R155C-K524A block protein
degradation, trigger Huntingtin aggregate formation, and
render cells highly susceptible to ER stress-induced cell death
as compared to VCPWTor other VCP mutants.
Keywords Valosin-containing protein.Endoplasmic
reticulum.ER stress.Programmed cell death
Abbreviations
VCP Valosin-containing protein
ER Endoplasmic reticulum
FTD Frontotemporal dementia
IBMPFD HereditaryinclusionbodymyopathywithPaget’s
disease of bone and FTD
Introduction
Accumulation of misfolded proteins induces cellular stress
including endoplasmic reticulum stress (ER stress), and
prolonged ER stress triggers neuronal apoptotic cell death
(Rao and Bredesen 2004; Bredesen et al. 2006; Yang et al.
2010). Studies from multiple laboratories have identified
the roles of several ER stress-induced cell death modulators
and effectors through the use of biochemical, pharmaco-
logical and genetic tools (Kopito 2000; Chen and Gao
2002; Forman et al. 2003; Hashimoto et al. 2003; Katayama
et al. 2004; Rao et al. 2004a; Xu et al. 2005; Bredesen et al.
2006; Lindholm et al. 2006; Yoshida 2007).
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DOI 10.1007/s12031-010-9489-8In our earlier studies, we used a set of complementary
approaches and identified valosin-containing protein (VCP)
as one of the mediators of ER stress-induced programmed
cell death (Rao et al. 2004a; Bredesen et al. 2006). Valosin-
containing protein, also known as p97, is a member of the
AAA (ATPases associated with diverse cellular activities)
family of ATP binding, homo-oligomeric ATPase proteins
and participates in multiple cellular activities, many of
which are regulated by the ubiquitin-proteasome (Ub-Pr)-
mediated degradation pathway (Vale 2000; Wang et al.
2003; Ju et al. 2009; Tresse et al. 2010). VCP consists of an
N-terminal domain and two ATPase domains D1 and D2,
both of which are required for mediating Ub-Pr degradation
(Egerton et al. 1992; Pleasure et al. 1993; Dai et al. 1998;
Dai and Li 2001; Hirabayashi et al. 2001; Song et al. 2003;
Vandermoere et al. 2006; Zhong and Pittman 2006). VCP
also functions as a sensor of abnormally-folded proteins
and has been reported to act as a cell death effector in
polyglutamine-induced cell death (Hirabayashi et al. 2001;
Kobayashi et al. 2002; Wojcik 2002; Doss-Pepe et al. 2003;
Zhong and Pittman 2006).
Recently, mutations in the VCP gene including R93,
R155, R191, and A232 were described that manifest
clinically as hereditary inclusion body myopathy (IBM)
with Paget’s disease of bone and frontotemporal dementia
(FTD; Schroder et al. 2005; Guyant-Marechal et al. 2006;
Hubbers et al. 2007; Halawani et al. 2009; Weihl et al.
2009; Custer et al. 2010). This multisystem disorder with
autosomal dominant inheritance is associated with disrup-
tion of normal VCP function leading to diffuse intracellular
accumulation of ubiquitinated proteins that may contribute
to the pathogenesis of IBMPFD (Inclusion Body Myopathy
associated with Paget’s disease of bone and Frontotemporal
Dementia; Weihl et al. 2006; Hubbers et al. 2007; Kimonis
et al. 2008;V i j2008; Gitcho et al. 2009; Vesa et al. 2009;
Weihl et al. 2009; Custer et al. 2010). Neurons, as well as
cells of the muscle, liver, and bone, are affected by these
mutations in VCP (Weihl et al. 2006; Gitcho et al. 2009;
Vesa et al. 2009; Weihl et al. 2009). In addition, a non-
clinical VCP mutant (K524A) located in the 2nd ATP
binding domain (D2 domain) induced large cytoplasmic
vacuoles and triggered programmed cell death (Hirabayashi
et al. 2001; Kobayashi et al. 2002).
In order to elucidate the biochemical and molecular
implications of such mutations in the cell we, introduced
analogous mutations (separately and together) into the VCP
gene to explore their impact on proteasome function,
Huntingtin protein aggregation and programmed cell death.
Our results demonstrate that, to varying degrees, these VCP
mutants: (1) disrupt VCP’s normal role in protein homeo-
stasis, (2) trigger the accumulation of ubiquitinated and
aggregated proteins that may be deleterious to the cell, and
(3) trigger cellular death.
Experimental Procedures
Cell Culture Conditions and Transfections
Human embryonic kidney (HEK) 293T cells were cultured
in DMEM containing 10% FBS and 1% penicillin/
streptomycin. Cells were maintained at 37°C and 5%
CO2. Transient transfection was performed as previously
described (Rao et al. 2001). In brief, 2×10
6 cells were
seeded into 10-cm dishes and transfected 1 day later with
6 μg of the specified construct using a ratio of 1 μg
DNA:5 μl of Lipofectamine 2000 transfection reagent
(Invitrogen, Carlsbad, CA). The transfection efficiency
using these conditions was typically about 65–75% as
determined by GFP transfection efficiency. Alternatively,
transfections for flow cytometry or immunocytochemistry
were carried out in multi-well dishes as specified in the
figures.
Generation of Constructs Encoding VCP Mutants Unless
otherwise stated, all molecular biology enzymes were
purchased from New England Biolabs (Ipswich, MA).
Expression plasmids encoding VCPWT and VCP K524A
in the pCMX backbone were kindly provided by Dr. A.
Kakizuka (Hirabayashi et al. 2001; Rao et al. 2004b).
The cDNAs encoding wild-type (WT) and K524A VCP
were transferred from the parent vectors by KpnI digestion
and ligation into the KpnI site of pcDNA3.1/Myc-His-A
(Invitrogen, Carlsbad, CA) and resultant ligation mixtures
transformed into DH5α competent cells (Invitrogen).
Clones possessing the VCP cDNAs in the correct orienta-
tion with regards to the cytomegalovirus promoter were
identified by PCR using the Failsafe DNA polymerase
(Epicentre Biotechnologies, Madison, WI). The resulting
pcDNA3.1/Myc-His-A/VCP construct was used as a
template for the addition of a BsmBI site containing a
partially destroyed HindIII site, a novel SacII site, and an
N-terminal FLAG tag sequence using PCR and the
oligonucleotides 5′ VCP FLAG and VCP HindIII Rev
(Table 1). The amplified product was digested with BsmBI
and HindIII, ligated into HindIII-digested pcDNA3.1/
Myc-His-A/VCP and pcDNA3.1/Myc-His-A/VCP K524A,
and transformed colonies were interrogated by PCR to
determine insert orientation. Resulting constructs named
pcDNA3.1/Myc-His-A/VCPWT-FLAG or pcDNA3.1/
Myc-His-A/VCPK524A-FLAG were evaluated by restriction
analysis to confirm that the 5′ KpnI site borrowed from the
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further confirmed by DNA sequencing.
As a result of this cloning strategy, it became possible to
separate the three desired mutations into individual modular
domains through the use of unique restriction sites. For
instance, the 5′~450 bp of VCP containing amino acid
residue 93 were restricted by SacII and HindIII, the amino
acid R155 was flanked by the sites HindIII on the 5′ and
NheI on the 3′ sides, and the amino acid K524 was flanked
by the sites NheI on the 5′ and the remaining KpnI site from
the original pCMX construct on the 3′ side. The R93C
mutant was created using pcDNA3.1/Myc-His-A/VCPWT-
FLAG as a template for PCR amplification to generate the
5′ R93C reaction product using the oligonucleotides 5′ VCP
FLAG and R93C REV and the 3′ R93C reaction product
using oligonucleotides R93C FOR and VCP HindIII REV
(Table 1). Both overlapping products were gel-purified,
combined, and amplified using the external 5′ VCP FLAG
and 3′ VCP HindIII REVoligonucleotides and the resulting
product was digested by SacII and HindIII and ligated into
the corresponding SacII and HindIII sites of pcDNA3.1/
Myc-His-A/VCPWT-FLAG to create the construct
pcDNA3.1/Myc-His-A/VCPR93C-FLAG. Similarly, the
R155C mutant was created using pcDNA3.1/Myc-His-A/
VCPWT-FLAG as a template for PCR amplification to
generate the 5′ R155C reaction product using the oligonu-
cleotides VCP HindIII FOR and R155C REV and the 3′
R155C reaction product using oligonucleotides R155C
FOR and VCP NheI REV (Table 1). Both overlapping
products were gel purified, combined, and amplified using
the external VCP HindIII FOR and VCP NheI REV
oligonucleotides and the resulting product was digested by
HindIII and NheI and ligated into the corresponding
HindIII and NheI sites of pcDNA3.1/Myc-His-A/
VCPWT-FLAG to create the construct pcDNA3.1/
Myc-His-A/VCPR155C-FLAG. VCPDM (double mutant
R93C, R155C) and VCPTM (triple mutant R93C, R155C,
K524A) were created by subcloning the desired fragments
into the appropriate locations using the matching unique
restriction sites described above in a modular fashion. All
constructs were verified by DNA sequencing and Western
blot analyses were performed to verify protein expression.
Other than some changes in the total number of amino
acids and the N-terminal tag, the Huntingtin protein (Htt)
expression constructs (gift from Dr L.M. Ellerby) used in
these studies included the GFP-tagged normal N-terminal Htt
fragment Htt23Q-(1–552) and the expanded polyQ-Htt144Q-
(1–552) that have been previously described (Igarashi et al.
2003; Schilling et al. 2006). The sequences of all constructs
were confirmed by DNA sequencing, and Western blot
analyses were performed to verify protein expression.
Cell Extracts, Cell Fractionation and Western Blotting
Whole cell extracts were prepared as described earlier (Rao
et al. 2001). Briefly, cells were collected and resuspended
in cell lysis buffer (500 mM HEPES, pH 7.6, 250 mM
NaCl, 0.1% Nonidet P-40, 5 mM EDTA) containing
complete-mini protease inhibitors (Roche). Resuspended
cells were sonicated three times for 30 s each, and unbroken
cells and membrane debris were removed by centrifugation
at 4° for 15 min at 20,000 × g. Cell-free extracts and
microsomes were prepared as previously described (Rao et
al. 2001, 2002, 2004b, 2006). Briefly, the 20,000 × g
supernatant that lacks whole cells, nuclei and mitochondria
was recentrifuged at 400,000 × g for 1 h at 4°C for the
preparation of microsomes. The resulting supernatant (S)
contains the soluble cytosolic fraction and the pellet (P)
represents microsomes (ER membranes and lumen pro-
teins) as well as Golgi membranes. Typically, 100 μgo f
cell extract was loaded for SDS-PAGE and Western blot
analysis as previously described (Rao et al. 2001, 2002,
2004b, 2006). PVDF membranes were probed with a
1:1,000 dilution of mouse anti-VCP monoclonal antibody
(BD-Transduction Laboratories) and a 1:500 dilution of
rabbit anti-GRP78 polyclonal antibody (Stressgen-Assay
Designs Life Sciences) as a standard marker protein for
ER.
Cell Death Analysis by Flow Cytometry Flow cytometry
analysis was performed as previously described (Egger et
al. 2007). Briefly, attached and floating cells were
collected by low-speed centrifugation after gentle trypsi-
nization and stained with 3 μg/ml GFP-Annexin-V and
2.5 μg/ml propidium iodide in Annexin-V binding buffer
(10 mM Hepes/NaOH, pH 7.4, 140 mM NaCl, 2.5 mM
CaCl2) and incubated at room temperature for 15 min.
Table 1 Primer design for the various VCP mutant constructs
R93C REV: TCCTAGGCGAACGCAGAGGTTATTCCG
FOR: CGGAATAACCTCTGCGTTCGCCTAGGA
VCP-HindIII REV: GGATGGGCCGATAAGCTTCCAGGAAGTACG
FOR: CGTACTTCCTGGAAGCTTATCGGCCCATCC
R155C REV: ACGCATCCCACCGCAGACAAGAAAAAT
FOR: QTTTTTCTTGTCTGCGGTGGGATGCGT
VCP-NheI REV: TCCTTTATCTGAGCTAGCTGCTTCCTGCAA
FOR: TTGCAGGAAGCAGCTAGCTCAGATAAAGGA
5′VCP-FLAG*- GAATTCCGTCT CA AGCT CCGCGG ATGGATTA
CAAGGATGACGACGATAAG ATG GCCTCTGGAGCCGATTCAA
*From left: BsmBI (italicized), HindIII complementary overhang
(bold), SacII site (italicized & underlined), start methionine and
FLAG-tag corresponding codons (bold & underlined)
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(BD Biosciences, San Jose, CA) where annexin-V (dying)
and propidium iodide (dead) positive cells were quanti-
fied. Data were processed using CellQuest Pro (BD
Biosciences).
Analysis of Ubiquitin–Proteasome Function by Transfection
with GFPu To investigate the specific role of VCP and its
mutants in protein aggregation and ubiquitin–proteasome
system function, we made use of a GFPu reporter construct
kindly provided to us by Dr. Ron Kopito (Stanford
University). The reporter consists of a short degron CL1
sequence fused to the COOH terminus of green fluorescent
protein; this fusion protein is referred to as GFPu. By
appending this short sequence to the C-terminus of GFP,
the protein becomes unstable and is constitutively degraded
by the proteasome. In the present study, 293T cells were
transfected with GFPu cDNA together with VCPWT or its
various mutants at a ratio of 1:3, respectively. After 24 h,
GFPu immunofluorescence accumulation was quantified by
flow cytometry (Bence et al. 2001; Bence et al. 2005; Egger
et al. 2007).
Immunocytochemistry HEK 293T cells were plated at 60–
75% confluency on glass coverslips. Twenty-four hours
after plating the cells, transfections were carried out as
mentioned above and following the manufacturer’s protocol
(Invitrogen). Twenty-four hours after transfection, samples
were treated with or without 1 μM thapsigargin for 24
hours. Cells were fixed in buffered 4% paraformaldehyde
and permeabilized in 0.2% Triton in PBS. For the detection
of VCP, cells were stained with mouse monoclonal anti-
VCP (BD-Transduction Laboratories, 1:200) and Alexa
Fluor 488 donkey anti-mouse IgG (4 μg/ml, Invitrogen,
Carlsbad, CA) as the secondary antibody. For the
detection of GRP78, cells were stained with rabbit
polyclonal anti-GRP78 (Santa Cruz Biotechnology, 1:100)
and Alexa Fluor 555 donkey anti-rabbit IgG (2 µg/ml,
Invitrogen, Carlsbad, CA). Nuclei were counterstained
using VectaShield Mounting Medium with DAPI (Vector
Laboratories, Burlingame, CA).
For confocal microscopy studies involving VCP and
Htt constructs, a similar staining procedure was followed.
Following transfection of 293T cells for 48 h with VCPWT
or mutants and Htt-23Q or Htt-144Q cDNA, cells were
fixed in 4% paraformadehyde in PBS for 20 min. After
three PBS washes, cells were permeabilized with 0.2%
Triton in PBS for 15 min and serially stained first for
Huntingtin and then for VCP in the following manner. Cells
were blocked for 30 min in 5% normal donkey serum
(NDS) in PBS. Mouse IgG anti-Huntingtin protein
(MAB2166, Chemicon) was diluted 1:50 in 2.5% NDS in
PBS and incubated overnight at 4°C. Cells were washed
three times in PBS and incubated in secondary antibody
(Alexa Fluor 555 donkey anti-mouse IgG, 2 µg/ml,
Invitrogen) diluted in 2.5% NDS for 1 h at room
temperature (RT). Cells were then washed three times in
PBS and re-blocked in 5% NDS with 0.3% Triton in PBS
for 30 min. Rabbit IgG anti-VCP (BD-Transduction
Laboratories) was diluted 1:50 in 0.3% Triton in PBS
and incubated overnight at 4°C. Cells were then washed
three times in PBS and incubated in secondary antibody
(Alexa Fluor 488 donkey anti-rabbit IgG, 4 µg/ml,
Invitrogen) diluted in 0.3% triton in PBS for 1 h RT.
Cells were again washed three times with PBS, air dried
and mounted with Prolong Gold with DAPI (Invitrogen
P36931). Confocal images were acquired using a Zeiss
LSM510 NLO with Argon 488 nm, 543 nm HeNe and
Coherent Chameleon XR 2p laser with appropriate
excitation and emission filters. For counting Htt aggre-
gates, three random fields in each sample were selected
and the cells containing aggregates were counted with
Bitplane Imaris 6.4 using the Spots module. From the
GFP-positive cells in a given field, total number of
aggregates were counted and averaged among the three
replicate fields containing at least 300 cells/sample. Units
are expressed as the average number of aggregates/cell
and are determined by quantifying the average number of
GFP aggregates per GFP-positive cells.
Statistical Analysis All experiments were performed at least
three times unless otherwise indicated. Data were statisti-
cally analyzed using one-way ANOVA followed by
between group comparisons using the Newman–Keuls
Multiple Comparison Test (GraphPad Prism, San Diego,
CA). Results are expressed as mean ± SEM, and a value of
p<0.05 was considered statistically significant.
Results
Expression of VCP Protein in ER Stress-Induced Cells VCP
functions as a sensor of abnormally folded proteins and has
been reported to act as a cell death effector (Wojcik 2002;
Rao et al. 2004b; Ju et al. 2008; Gitcho et al. 2009). The
naturally occurring VCP mutants R93C and R155C are
associated with frontotemporal dementia and inclusion
body myopathy (Kimonis et al. 2008; Gitcho et al. 2009).
To understand how these mutations might affect VCP
function, we designed analogous mutations separately
(single mutants) and together (double or triple mutants)
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cellular homeostasis. As shown in Fig. 1a, the expression
levels of VCPWT and the various mutant forms were very
similar in HEK 293T cells. To examine the subcellular
localization of VCPWT and its mutant forms before and/or
after ER stress induction, HEK 293T cells were transfected
with the various VCP constructs and either left untreated or
treated with 1.0 μM thapsigargin. Microsomes (400,000 × g
pellet (P)) and the 400,000 × g supernatant (S) isolated
from cell-free cytosolic extracts that lack whole cells,
nuclei, and mitochondria were subjected to SDS-PAGE
and Western blot analysis. As shown in Fig. 1b, both
VCPWT and its mutant forms again displayed a similar
level of expression. Whereas VCP and its mutant forms
were predominantly present in the cytosolic fraction (S)
before ER stress, there was increased presence in the
microsomal fraction (P) with thapsigargin treatment. A
similar pattern of expression was also seen in cellular
extracts isolated from cells treated with 2.5 μM brefeldin or
0.1 mg/ml tunicamycin (data not shown).
It is not clear from Fig. 1 if cellular stress is triggering
induction of VCP protein expression and/or causing cellular
redistribution of VCP. Earlier studies have shown that
cellular stress triggers both transcriptional induction and/or
cellular relocalization of several ER-associated proteins
responsible for the ER-associated degradation (ERAD)
pathway including GRP78, VCP and HSP90 that direct
the ubiquitin-mediated degradation of a variety of ER-
associated misfolded and normal proteins (Wojcik 2002;
Mimnaugh et al. 2006; Ju et al. 2009).
The localization of VCP was also investigated using
immunocytochemistry on untreated and thapsigargin-
treated cells using a VCP-specific antibody. As shown in
Fig. 1c, the antibody to VCP stained within the cytosolic
compartment with a somewhat diffuse granular pattern in
the control cells (green). GRP78, a marker protein for ER,
demonstrated punctate staining predominantly in the ER
(red). Virtually no co-localization of GRP78 and VCP
occurred under control conditions (merged). After treatment
with 1.0 μM thapsigargin for 24 h, VCP staining was more
intense, and this increased staining was associated with the
ER. GRP78 staining also became more intense, appeared
granular predominantly in the ER, and also displayed some
diffuse distribution in the cytoplasmic region. Following
thapsigargin treatment, approximately half the green fluo-
rescent volume (VCP) in the treated sample was found to
co-localize with GRP78. A similar pattern of cellular
localization before and after ER stress was seen in cells
transfected with the VCP mutants (data not shown). These
data suggest that ER stress not only increases the
expression of VCP but also triggers a subpopulation of
VCP to associate with the microsomal compartment as
described earlier (Mimnaugh et al. 2006).
Expression of VCP Mutants Triggers Cell Death Earlier
reports indicated that VCP is a major mediator of ER
stress-induced apoptosis and the inhibition of VCP
expression resulted in a reduction of ER stress-induced
c e l ld e a t h( R a oe ta l .2004a). The naturally-occurring
and clinically-described VCP mutants R93C, R155C, and
R191A demonstrate a cellular phenotype in which their
mediation of cell death is increased (Kimonis et al. 2008;
Gitcho et al. 2009). To better understand this phenome-
non, we transfected HEK 293T cells with single, double,
or triple mutants of VCP and treated the cells with
2.5 μM thapsigargin for 48 h. As shown in Fig. 2,f l o w
cytometry analysis revealed that treatment with thapsi-
gargin led to approximately 30% cell death in cells
transfected with VCPWT, R93C, R155C or DM (double
mutant R93C, R155C). However, cells transfected with
VCP K524A or TM (triple mutant R93C, R155C,
K524A) showed an increased susceptibility to cell death
triggered by thapsigargin; over 40% of the cells trans-
fected with VCP K524A or TM were GFPAnnexin-V-
positive with thapsigargin treatment and had significantly
more cell death than did VCPWT.
The VCP K524A mutant has previously been shown to
induce large cytoplasmic vacuoles and eventually trigger
cell death (Hirabayashi et al. 2001; Kobayashi et al. 2002;
Manno et al. 2010). While both the VCP K524A single
mutant and the VCP TM (triple mutant that includes the
K524A mutation) produced a clear effect on cell death, the
clinically relevant FTD-associated mutants alone did not.
Earlier reports on other chaperone proteins possessing an
intrinsic ATPase activity demonstrate that abolishing the
ATPase activity either through base mutations or specific
inhibitors causes ER disruption, prevents substrate binding,
inhibits chaperone function and triggers cytostasis or cell
death (Zhang and Kaufman 2006; Egger et al. 2007; Mishra
et al. 2007; Seki et al. 2007; Gitcho et al. 2009; Ju et al.
2009). Thus, it appears that inactivation of the ATPase
activity of VCP (K524A and VCP TM) may disrupt a broad
spectrum of cellular functions through its binding to
specific substrates.
VCP Regulates Ubiquitin-Proteasome Function p97/VCP
is believed to be a cellular sensor protein that detects
abnormal protein accumulation in the cell and promotes
their degradation through the ubiquitin–proteasome system
(UPS) in a phenomenon called ERAD (Weihl et al. 2006;
Zhong and Pittman 2006;V i j2008; Gitcho et al. 2009;
Yang et al. 2010). To better understand how FTD-related
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of a fluorescent GFPu protein construct. By appending a
short degron sequence CL1 to the C terminus of GFP,
the GFPu protein is constitutively degraded by the
proteasome (Bence et al. 2005). Thus, GFPu is unstable
as compared to normal GFP, but in the presence of the
selective proteasome inhibitors lactacystin or ALLN (N-
acteyl-leucine-leucinenorleucinal), the UPS-mediated deg-
radation of GFPu is blocked, leading to increased steady-
state GFPu levels (Bence et al. 2005; Egger et al. 2007).
To assess the effect of the VCP mutants on GFPu
stability/accumulation, HEK 293T cells were co-transfected
with GFPu and VCPWT or its various mutants and
analyzed for GFPu fluorescence by flow cytometry. As
shown in Fig. 3, while cells transfected with VCPWT,
R93C, R155C or DM had relatively low levels of GFPu
fluorescence, cells transfected with VCP K524A or the TM
resulted in an accumulation of GFPu and substantially
increased GFPu fluorescence. GFPu fluorescence was
approximately 1.5-fold higher in cells transfected with
VCP K524A or the TM than that of VCPWT, suggesting
that the presence of VCP K524A led to a partial inhibition
of the UPS. The results also suggest that GFPu degradation
is VCP dependent and requires an intact D2-ATPase
domain (Kimonis et al. 2008; Gitcho et al. 2009; Halawani
et al. 2009).
Effect of VCP Mutants on Poly (Q) Huntingtin Protein
Degradation Since expression of VCP K524A and the
K524A-containing triple mutant led to inhibition of the
UPS, we looked to see whether VCP and its mutants alter
poly(Q) huntingtin protein degradation and turnover, with
the rationale for these studies being that VCP has been
shown to interact with huntingtin as well as other polyglut-
amine proteins (Kobayashi et al. 2002; Ju et al. 2008; Yang
et al. 2010). We co-expressed VCP and its mutants in HEK
293T cells together with GFP-tagged Htt-23Q or expanded
Htt-144Q and also quantified the number of Htt-poly
R Fig. 1 Expression and subcellular localization of VCP before and
after ER stress. a Western blot of whole cell extracts prepared from
HEK293T cells transfected with VCPWT, R93C, R155C, K524A,
R93C/R155C (double mutant; DM) or R93C/R155C/K524A (triple
mutant; TM) cDNA construct as described in “Experimental Procedures”.
Samples (100 μg protein) were analyzed by SDS-PAGE followed
by Western blotting with an anti-VCP antibody. b 293T cells were
transfected with VCPWT, R93C, R155C, K524A, or the TM cDNA
construct. After 24 h, cells were either left untreated or treated with
1.0 μM thapsigargin (Thaps) for 24 h. Microsomes were isolated
from cell extracts as described in “Experimental Procedures” and
100 μg protein from the 400,000 × g supernatant (S)o rm i c r o s o m a l
(P) fractions was subjected to SDS-PAGE and Western blotting.
Membranes were probed with an anti-VCP antibody or anti-GRP78
antibody that served as a standard marker protein for ER. c
Immunofluorescent staining for VCP and GRP78 in untreated or
1.0 μM thapsigargin-treated HEK293T cells. 24 h after treatment,
cells were fixed in buffered 4% paraformaldehyde. For the detection
of VCP, cells were stained with a mouse monoclonal anti-VCP
antibody as primary antibody and 488-conjugated donkey anti-
mouse IgG as the secondary antibody (green). For the detection of
GRP78, cells were stained with rabbit polyclonal anti-GRP78
antibody as primary antibody and 555-conjugated donkey anti-
rabbit IgG as the secondary antibody (red). Nuclei are counterstained
using VectaShield Mounting Medium with DAPI
* 
* 
VCP WT  VCPK524 
VCP DM VCP TM 
* 
A B 
Fig. 2 Expression of VCP mutants triggers cell death. HEK293T cells
were transfected with either VCPWT, R93C, R155C, K524A, DM
(R93C, R155C) or TM (R93C, R155C, K524A) cDNA construct and
treated for 48 h with 2.5 μM thapsigargin. Cells were gently lifted,
stained with GFP-annexin-Vand propidium iodide and assessed for cell
death by flow cytometry as described in “Experimental Procedures”. a
Representative dot plots from fluorescently-stained cells are shown with
annexin-V positive dying and dead cells occupying the area on the right
side of the plot. b Bar graph represents the percent of annexin-V
positive cells. Data (mean ± SEM) are from three independent
experiments analyzed by one-way ANOVA followed by Newman–
Keuls Multiple Comparison Test (*p<0.01, **p<0.001 as compared to
VCP WT)
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transfected with normal length Htt-23Q exhibited far fewer
aggregates than the expanded Htt-144Q in the presence of
either VCPWT or the mutant forms. However, in the
presence of VCP K524A, DM or TM, even normal length
Htt-23Q had a high tendency to aggregate into cytoplasmic
and nuclear inclusions while cells expressing the expanded
Htt-144Q displayed aggregates that were nearly two-fold
higher (Fig. 4b), further suggesting a role for VCP in UPS-
mediated protein degradation (Bence et al. 2001; Kobayashi
et al. 2002). Earlier reports have shown that Poly(Q)–
containing proteins such as huntingtin and ataxin bind VCP
and decrease retrotranslocation of substrates from the ER
resulting in decreased degradation of ERAD substrates
(Weihl et al. 2006; Zhong and Pittman 2006;V i j2008;
Gitcho et al. 2009; Yang et al. 2010). This raises the
possibility that excessive binding between VCP and poly
(Q) proteins over an extended period of time or during
times of increased cellular stress shifts a physiological
regulation to a pathophysiological uncoupling of ERAD
which may then contribute to disease pathogenesis
(Hirabayashi et al. 2001; Higashiyama et al. 2002;D o s s -
Pepe et al. 2003; Boeddrich et al. 2006; Zhong and
Pittman 2006).
Discussion
VCP is involved in three distinct processes all related to cell
death and neurodegeneration: (1) VCP is required for ER
stress-induced programmed cell death where it functions as
a sensor of abnormally folded proteins (Rao et al. 2004b);
(2) naturally occurring VCP mutations are associated with
the neurodegenerative disease IBMFTD when they are part
of a syndrome that includes FTD, Paget’s disease of bone,
and inclusion body myopathy (Schroder et al. 2005;
Forman et al. 2006; Guyant-Marechal et al. 2006; Hubbers
et al. 2007; Halawani et al. 2009; Weihl et al. 2009; Custer
et al. 2010); and (3) our present results also indicate that
VCP mutations, and in particular the K524A ATPase
mutant, perturb normal VCP functions, including altering
the ubiquitin–proteasome system, triggering abnormal
protein aggregation and accumulation leading to increased
cell death.
VCP has two ATPase domains (D1 and D2) and
belongs to the AAA class of proteins that also includes
NSF (N-ethylmaleimide-sensitive fusion protein),
Hsp104p (heat shock protein 104) and p97/Cdc48p
(ortholog of VCP in yeast) (Vale 2000; Song et al. 2003;
Halawani et al. 2009). Intact ATPase activity is required
for various biological functions of VCP including an
intrinsic chaperone activity and binding to ubiquitinated
proteins and presenting them to the UPS for degradation
(Song et al. 2003;V i j2008;G i t c h oe ta l .2009;M a n n oe t
al. 2010). While the D1-ATPase domain forms a relatively
stable ring and holds the VCP hexamer together through-
out the ATPase cycles, the conformational changes
induced by the nucleotide binding is mainly attributed to
the D2-ATPase domain (Song et al. 2003).
All the clinical mutations of VCP associated with the
neurodegenerative disease IBMFTD described thus far
reside within the N-terminus and D1-ATPase domain,
regions that are proposed to be involved in substrate
binding and cofactor association (Watts et al. 2004;J u
et al. 2009). Biochemical characterization of these VCP
mutations indicates that not only do they form stable
hexamers but they also have increased ATPase activity and
efficiently bind to co-chaperone proteins that are essential
for UPS function (Hubbers et al. 2007; Halawani et al.
2009; Ju et al. 2009). The increased ATPase activity may
also reflect structural changes upon ATP binding (Halawani
et al. 2009). Moreover, mutations in the VCP gene may
result in the disruption of normal VCP function leading to
diffuse intracellular accumulation of ubiquitinated proteins
that may contribute to the disease pathogenesis.
Our present studies and reports from other groups
indicate that despite exhibiting reduced ATPase activity,
the K524A mutant functions similarly to the clinical
mutants by perturbing normal VCP functions and
Fig. 3 Analysis of proteasome activity. Proteasome activity was
determined by measuring the accumulation of green fluorescence in
cells transiently transfected with GFPu together with the VCP
mutants. HEK 293T cells were transfected with VCPWT, R93C,
R155C, K524A, DM (R93C, R155C) or TM (R93C, R155C, K524A)
cDNA construct together with GFPu. Twenty-four hours after
transfection, accumulation of GFPu fluorescence was measured by
flow cytometry. The bar graph represents the percent of cells positive
for GFPu fluorescence. Data (mean ± SEM) are from two independent
experiments analyzed by one-way ANOVA followed by Newman–
Keuls Multiple Comparison Test (*p<0.05, **p<0.01 as compared to
VCPWT)
98 J Mol Neurosci (2011) 44:91–102triggering abnormal protein aggregation and accumula-
tion leading to increased cell death (Hirabayashi et al.
2001; Kobayashi et al. 2002; Manno et al. 2010). This
suggests that the substrate binding to the N-terminal
portion of VCP mutants may affect its D2-ATPase activity
and function similarly to the VCP K524A or TM (R93C/
R155C/K524A) which may then interfere with ubiquitin-
dependent pathways thereby leading to abnormal protein
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Fig. 4 Analysis by confocal microscopy of GFP-Htt aggregation after
co-transfection with VCP constructs. a Following transfection of 293T
cells with VCPWT, K524A, DM (R93C, R155C) or TM (R93C,
R155C, K524A) cDNA construct together with Htt-23Q or Htt-144Q,
cells were permeabilized as mentioned in “Experimental Procedures”
and serial stained first for Huntington protein and then for VCP as
described in “Experimental Procedures”. Confocal images were
acquired using a Zeiss LSM510 NLO with Argon 488 nm, 543 nm
HeNe and Coherent Chameleon XR 2p laser with appropriate
emission filters. b Quantification of Htt aggregates in VCPWT or
VCP mutant-expressing cells. Htt aggregates were counted with
Bitplane Imaris 6.4 using the Spots module as described in
“Experimental Procedures”. From the GFP-positive cells in a given
field, total number of aggregates were counted and averaged among
the three replicate fields containing at least 300 cells/sample. Units are
expressed as the average number of aggregates/cell and are deter-
mined by quantifying the average number of GFP aggregates per
GFP-positive cells
J Mol Neurosci (2011) 44:91–102 99aggregation in the nucleus and cytoplasm as well as
enhanced cell death. Interestingly, NSF(K549A), an NSF
mutant containing an equivalent mutation to VCP
(K524A), has been reported to lose its ATPase activity
a n dA T Pb i n d i n ga n dh a sb e e np r o p o s e dt of u n c t i o ni na
dominant-negative manner within the NSF hexameric
complex (Whiteheart et al. 1994).
Transgenic mice expressing the IBMPFD clinically
relevant VCP mutant forms develop abnormal muscle
pathology including coarse internal architecture, vacuo-
lation, and disorganized membrane morphology with
reduced caveolin-3 expression at the sarcolemma (Weihl
et al. 2007;C u s t e re ta l .2010). These animals also display
an increase in ubiquitin-containing protein inclusions and
high molecular weight ubiquitinated proteins suggesting
that the early and persistent increase in ubiquitinated
proteins induced by IBMPFD mutations in p97/VCP may
ultimately lead to animal weakness and the observed
muscle pathology (Weihl et al. 2007; Custer et al. 2010).
The in vivo effects are thus hypothesized to be due to an
accumulation of misfolded proteins such that, in neuronal
tissues with a lower rate of turnover, the effect would be
degeneration (such as FTD), whereas surviving cells
would feature accumulated misfolded proteins and thus
inclusion bodies (such as IBM). It would be interesting to
understand if more noticeable phenotypes could be
uncovered if mutant VCP were to replace endogenous
VCP with the rationale being that there would be a greater
likelihood of seeing more profound effects of the FTD
mutants if endogenous VCP were knocked down. It is also
possible that future studies examining parameters other
than the ones we chose to study in this work or using other
model systems could uncover effects of the clinically
relevant VCP mutants.
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